For selected early stage small cell lung cancer (SCLC), curative intent surgery is often performed. Previous studies, predominantly from East Asia, reported that high neutrophil to lymphocyte ratio ...(NLR), and platelet-lymphocyte ratio (PLR) correlate with poor prognosis in several types of tumors including SCLC. Our aim was to investigate the prognostic value of NLR and PLR in Caucasian patients with resected SCLC, as potential tool to select patients for multimodal treatment including surgery.
Consecutive patients evaluated at three centers between 2000 and 2013 with histologically confirmed and surgically resected SCLC were retrospectively analyzed. NLR and PLR at diagnosis was used to categorize patients into "high" and "low" groups based on receiver operating curve analysis. Univariate and multivariate analyses were used to evaluate the impact of clinical and pathological characteristics on outcome.
There were a total of 189 patients with a median age of 58 years, and the majority had stage I or II disease. We found a significant correlation between NLR and tumor stage (
= 0.007) and age (
= 0.038). Low NLR (LNLR) was associated with significantly longer overall survival, while PLR had no prognostic impact. There were significant associations between NLR and PLR but not with gender, vascular involvement, tumor necrosis, peritumoral inflammation, or tumor grade.
Pre-operative LNLR may be a favorable prognostic factor in stage I-II SCLCs. PLR is not prognostic in this population. LNLR is easy to assess and can be integrated into routine clinical practice. Further prospective studies are needed to confirm these observations.
Aims
A better understanding of treatment patterns and outcomes in different countries should improve the management of patients with gastric cancer globally. The REgistry of GAstric Cancer Treatment ...Evaluation (REGATE) study was established to evaluate variations in gastric cancer disease characteristics and treatment patterns in different parts of the world.
Methods
REGATE was a prospective international registry enrolling patients with newly diagnosed gastric cancer at any stage of the disease.
Results
A total of 10 299 patients (65% male; mean age 59 years) were recruited in 22 countries between 2004 and 2008. Tumor location at a proximal site was more common in Europe, Latin America and North Africa (approximately 20%) than in Asia‐Pacific, where antral location predominated. Signet‐ring cell histology predominated except in Europe, where adenocarcinoma was most prevalent. Stage I cancers were more frequent in Asia‐Pacific (39%) versus other regions (6−18%), whereas stage IV cancers were more frequent outside Asia‐Pacific. Surgery was planned for most patients, although in general fewer patients actually received surgery than originally planned. Adjuvant therapy and palliative care were generally used more frequently than originally planned. Overall, 15% of patients received no treatment (Asia‐Pacific 8%; Indian subcontinent 25%).
Conclusions
These results provide a comprehensive database representative of gastric cancer disease characteristics and treatment patterns across the world.
Aims
The objective of the registry of gastric cancer treatment evaluation (REGATE) study was to evaluate approaches to gastric cancer treatment in different geographical regions.
Methods
REGATE ...enrolled patients with newly diagnosed gastric cancer at any stage of the disease from the Asia–Pacific region, Europe, the Indian subcontinent, Latin America and North Africa between 2004 and 2008.
Results
Among 9965 patients, 69% received surgery, 40% palliative care, 29% adjuvant therapy and 2% neoadjuvant therapy; 15% received no treatment. Combination treatment (mostly surgery/adjuvant) was used in one‐third of patients. Overall, 90% received chemotherapy (mostly fluoropyrimidine/platinum combinations but with marked geographical variation) and 21% received radiotherapy. Curative surgery alone was used most frequently for stages 0–II cancers and was employed more often in Europe (55%) and the Asia–Pacific (48%) than in other regions (27–35%). Asia–Pacific and Indian subcontinent patients were more likely to have a distal subtotal gastrectomy and less likely to undergo total gastrectomy than patients in other regions. Lymph node D2 dissection was favored in the Asia–Pacific, Europe and Latin America, whereas D1 dissection was used more in the Indian subcontinent and North Africa.
Conclusion
These data showing geographical differences in the approaches to gastric cancer treatment may promote the optimization of the management of gastric cancer globally.
The objectives of this study were to evaluate the safety profile of aflibercept and health-related quality of life (HRQL) in patients with metastatic colorectal cancer (mCRC) provided with ...aflibercept access before marketing authorization.
Patients received aflibercept followed by FOLFIRI (fluorouracil, leucovorin, irinotecan) on day 1 of a 2-week cycle until disease progression, unacceptable toxicity, death, or patient/investigator decision to discontinue. Treatment-emergent adverse events (TEAEs) were evaluated, and HRQL was assessed at baseline, cycle 3, and every other cycle using the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30, EORTC QLQ-CR29, and EuroQol 5-Dimensions 3-Levels questionnaires (NCT01571284).
Overall, 779 adult patients with mCRC, who received ≥ 1 prior oxaliplatin-based regimen and had disease progression during or following their last administration of oxaliplatin-based chemotherapy, were enrolled. At data cutoff, all patients had discontinued treatment, mainly owing to disease progression (51.7%). The most common TEAEs of any grade were diarrhea (61.6%), hypertension (48.4%), and nausea (43.3%). The most common grade 3/4 TEAEs were hypertension (24.1%), neutropenia (23.1%), and diarrhea (15.3%). Clinically meaningful changes in HRQL were reported for all measures. Most patients either had an improvement in their HRQL scores or remained stable during the treatment period based on patient-reported outcomes.
The data from this study support the tolerability of the combination of aflibercept and FOLFIRI in a setting that more closely approximates real life in patients with mCRC who failed to respond to oxaliplatin-based chemotherapy, and also suggest an improvement in HRQL.
This study evaluated safety and quality of life in patients with metastatic colorectal cancer undergoing treatment with aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan). Most patients treated with this combination experienced either improvement or stability in quality of life scores. Aflibercept plus FOLFIRI is tolerable in the treatment of patients with metastatic colorectal cancer with a safety profile similar to that seen in previous studies of these individual medications.
Background
Perioperative complications can affect outcomes after gastrectomy for cancer, with high mortality and morbidity rates ranging between 10 and 40%. The absence of a standardized system for ...recording complications generates wide variation in evaluating their impacts on outcomes and hinders proposals of quality-improvement projects. The aim of this study was to provide a list of defined gastrectomy complications approved through international consensus.
Methods
The Gastrectomy Complications Consensus Group consists of 34 European gastric cancer experts who are members of the International Gastric Cancer Association. A group meeting established the work plan for study implementation through Delphi surveys. A consensus was reached regarding a set of standardized methods to define gastrectomy complications.
Results
A standardized list of 27 defined complications (grouped into 3 intraoperative, 14 postoperative general, and 10 postoperative surgical complications) was created to provide a simple but accurate template for recording individual gastrectomy complications. A consensus was reached for both the list of complications that should be considered major adverse events after gastrectomy for cancer and their specific definitions. The study group also agreed that an assessment of each surgical case should be completed at patient discharge and 90 days postoperatively using a Complication Recording Sheet.
Conclusion
The list of defined complications (soon to be validated in an international multicenter study) and the ongoing development of an electronic datasheet app to record them provide the basic infrastructure to reach the ultimate goals of standardized international data collection, establishment of benchmark results, and fostering of quality-improvement projects.
PDF
